Frequency, indication and evolution of emergency cardiac surgery during TAVI

Original Title: Emergent cardiac surgery during transcatheter aortic valve implantation (TAVI): insight the Edwards SAPIENS Aortic Bioprosthesis Outcome (SOURCE) registry. Reference: Holger Eggerbrecht, et al. EuroIntervention 2014;10:975-81

SOURCE register data from patients receiving transcatheter aortic valve implantation with the Edwards Sapiens valve, were analyzed; out of 2307 patients, 27 (1.2%) required emergency cardiac surgery (ECS).

Valve stenosis was equally severe, but the aortic annulus diameter was larger in those that required ECS; this difference increased when using a

ECS causes were embolism/migration in 9 patients, aortic injury (dissection and perforation) in 7, aortic annulus rupture in 3, severe aortic regurgitation in 3, myocardial tamponade in 2, transapical bleeding in 1, heart block in 1 and suboptimal valve deployment in 1. 10 ECS patients died within 72 hours (VARC-2). At 30 days, mortality was 51.9% vs. 7.8% of those that did not require ECS (p<0.001). At 90 days, mortality was even higher, reaching 70% (19/27).

Conclusion

ECS rates in the context of TAVI is very low (1.2%), it should be performed with no delay and is associated with a 52% mortality rate at 30 days. Severe complications with acute evolution (annulus rupture or aortic injury) presented even higher mortality rates.

Commentary

This study, as well as others, has shown that although ECS during TAVI is not a frequent procedure, it unfortunately has high mortality rates within 90 days. This depends on the type of complications it may cause, and calls for a technological effort to develop more flexible and better adjusted valves to avoid these complications. 

Courtesy of Dr. Carlos Fava
Interventional Cardiologist
Favaloro Foundation – Buenos Aires

Carlos Fava

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...